- Ki20227
-
- $1.00 / 1g
-
2020-01-13
- CAS:623142-96-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 1ton
|
| | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea Basic information |
| Product Name: | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea | | Synonyms: | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea;Urea, N-[4-[(6,7-diMethoxy-4-quinolinyl)oxy]-2-Methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-;1-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-3-(1-(thiazol-2-yl)ethyl)urea;1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea;KI20227; KI-20227; KI 20227;CS-1094;KI20227; KI 20227;Ki20227 | | CAS: | 623142-96-1 | | MF: | C24H24N4O5S | | MW: | 480.54 | | EINECS: | 200-258-5 | | Product Categories: | | | Mol File: | 623142-96-1.mol | ![N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea Structure](CAS/GIF/623142-96-1.gif) |
| | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea Chemical Properties |
| Boiling point | 621.8±55.0 °C(Predicted) | | density | 1.327 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | ≥48.1 mg/mL in DMSO; insoluble in H2O; ≥8.6 mg/mL in EtOH with gentle warming and ultrasonic | | form | Brown powder. | | pka | 12.03±0.46(Predicted) |
| | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea Usage And Synthesis |
| Description | Ki20227 is an inhibitor of macrophage colony stimulating factor 1 (CSF1) receptor tyrosine kinase (c-Fms; IC50 = 2 nM). It inhibits CSF1-dependent c-Fms phosphorylation in a dose-dependent manner in RAW264.7 cells and reduces CSF1-dependent growth of M-NFS-60 cells (IC50 = 14 nM). Ki20227 suppresses development of TRAP-positive osteoclast-like cells from murine bone marrow (IC50 = 40 nM) and decreases the number and area of osteolytic lesions on femurs and tibiae in a murine A375 subcutaneous xenograft model. Ki20227 also reduces TNF-α infiltration and osteolytic bone destruction in a collagen-induced arthritis (CIA) mouse model. | | Uses | Ki 20227 is a c-fms tyrosine kinase inhibitor, which suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. | | in vitro | ki20227 was found to inhibit c-fms, kdr, c-kit, and platelet-derived growth factor receptor b, but not inhibit other kinases tested, such as epidermal growth factor receptor, fms-like tyrosine kinase-3 , or c-src. ki20227 was also found to inhibit the m-csf dependent growth of m-nfs-60 cells but not the m-csf independent growth of a375 human melanoma cells. furthermore, ki20227 inhibited the development of tartrate-resistant acid phosphatase-positive osteoclast-like cells in a dose-dependent manner [1]. | | in vivo | oral administration of ki20227 suppressed osteoclast-like cell accumulation and bone resorption induced by metastatic tumor cells in nude rats following intracardiac injection of a375 cells. in addition, ki20227 decreased the number of tartrate-resistant acid phosphatase-positive osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats [1]. | | storage | Store at +4°C | | references | [1] ohno h, kubo k, murooka h, kobayashi y, nishitoba t, shibuya m, yoneda t, isoe t. a c-fms tyrosine kinase inhibitor, ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. mol cancer ther. 2006;5(11):2634-43. |
| | N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea Preparation Products And Raw materials |
|